CHSY.F Stock Overview
An investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People’s Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 5/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
China Medical System Holdings Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.93 |
| 52 Week High | HK$0.93 |
| 52 Week Low | HK$0.93 |
| Beta | 0.83 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | -38.69% |
| 3 Year Change | -61.22% |
| 5 Year Change | -4.05% |
| Change since IPO | 3.99% |
Recent News & Updates
Recent updates
Shareholder Returns
| CHSY.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | 3.7% | -2.2% |
| 1Y | -38.7% | -0.7% | 18.3% |
Return vs Industry: CHSY.F underperformed the US Pharmaceuticals industry which returned 18.5% over the past year.
Return vs Market: CHSY.F underperformed the US Market which returned 16.9% over the past year.
Price Volatility
| CHSY.F volatility | |
|---|---|
| CHSY.F Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 17.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CHSY.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine CHSY.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 5,701 | Kong Lam | web.cms.net.cn/zh/home/ |
China Medical System Holdings Limited, an investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People’s Republic of China. Its products include VALTOCO, a diazepam nasal spray to treat seizure clusters; Plendil for the treatment of hypertension and stable angina pectoris; XinHuoSu to treat acute heart failure; Deanxit for mild-to-moderate depression, anxiety, and psychosomatic affections; METOJECT, a methotrexate injection for recalcitrant disabling psoriasis; and Ursofalk for the treatment of cholesterol gallstones in the gallbladder, cholestatic liver disease, and biliary reflux gastritis. The company also offers Salofalk for treating Ulcerative Colitis and Crohn’s disease; Bioflor for the treatment of diarrhea; Combizym for dyspepsia; ILUMETRI, a tildrakizumab injection to treat moderate-tosevere plaque psoriasis; Augentropfen Stulln Mono eye drops to treat senile macula degeneration and asthenopia; and Hirudoid for blunt traumata with or without hematomas and superficial phlebitis insofar.
China Medical System Holdings Limited Fundamentals Summary
| CHSY.F fundamental statistics | |
|---|---|
| Market cap | US$1.98b |
| Earnings (TTM) | US$330.82m |
| Revenue (TTM) | US$1.10b |
6.0x
P/E Ratio1.8x
P/S RatioIs CHSY.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CHSY.F income statement (TTM) | |
|---|---|
| Revenue | CN¥8.01b |
| Cost of Revenue | CN¥1.94b |
| Gross Profit | CN¥6.08b |
| Other Expenses | CN¥3.68b |
| Earnings | CN¥2.40b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.98 |
| Gross Margin | 75.82% |
| Net Profit Margin | 29.96% |
| Debt/Equity Ratio | 8.3% |
How did CHSY.F perform over the long term?
See historical performance and comparisonDividends
6.7%
Current Dividend Yield40%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/07/29 21:42 |
| End of Day Share Price | 2024/05/01 00:00 |
| Earnings | 2023/12/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
China Medical System Holdings Limited is covered by 33 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jessica Li | BofA Global Research |
| Lok Kwan Chiu | CCB International Securities Limited |
| Harry He | China Galaxy International Securities (Hong Kong) |